Phaseline

Companies › Anhui HygeianCells BioMedical

Anhui HygeianCells BioMedical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ceAF (Animal early embryo extract)
Cell-free biological preparation from early chick embryo amniotic fluid containing composi
–Phase 1Knee Arthritis, OsteoarthritisMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07902128ceAF (Animal early embryo extract)Phase 1Knee Arthritis, OsteoarthritisImmunologyMar 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.